Global Influenza Vaccine Market: Overview
The viral infection is caused due to the flu known as influenza in the respiratory system. Influenza virus enters the human body with the help of respiratory droplets and is contagious. It can spread from one person to another with physical contact or random face-to-face communication. The influenza virus keeps on circulating in the whole body continuously, along with the several outbreaks and regional epidemics that lead to severe death cases. The transforming building structure of the virus is inducing a massive change in vaccines to match the blueprint of changing influenza virus strain. The medicare organizations across the globe, including the centers for disease control and prevention, are advising several vaccines like baloxavir marboxil (Xofluza) for treating such flu or influenza in the body. The vaccines developed for treating influenza are made in combination of three different viruses, including influenza type A with H1N1, type B virus strain, and influenza type A H3N2 virus strain.
Report Scope:
Report Attribute | Details |
---|---|
Base Year | 2020 |
Historic Years | 2016 - 2020 |
Forecast Years | 2021 - 2028 |
Segments Covered | By Product Type, By Application, and By End Use |
Forecast Units | Value (USD Billion), and Volume (Units) |
Quantitative Units | Revenue in USD million/billion and CAGR from 2021 to 2028 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World |
Countries Covered | U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others |
Number of Companies Covered | 10 companies with scope for including additional 15 companies upon request |
Report Coverage | Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis. |
Customization Scope | Avail customized purchase options to meet your exact research needs. |
Global Influenza Vaccine Market: Growth Factors
The growing prevalence of influenza epidemics is likely to steer the growth of the global influenza vaccine market during the forecast period. The frequent seasonal outbreaks globally are further likely to expand the sales of such vaccine products over the projected period. The constantly growing government support and favorable policies regarding vaccination against viruses like influenza on the global level are likely to further support the market growth. Furthermore, the government effectively administers and monitors the distribution and supply of flu vaccines. Market players are fuelling the investments and the government is also rising its funding to launch therapeutically advanced and effective vaccines for influenza. The immunization programs and camps are conducted by several medical organizations. However, vaccine development is a very tedious and time taking process that generally ranges from around 10 to 15 years to establish the efficacy and safety of vaccines. But several regulatory amendments and modifications are done in several countries to avoid the delay in the development of vaccines, which in turn is likely to be the crucial factor for the development of the global influenza vaccine market. Companies are highly involved in research and development activities to bring innovative vaccines to the market. The outbreak of the Covid-19 pandemic globally is likely to fuel the demand for influenza vaccines in the market. However, it has significantly led people to take vaccines even in the normal flu as a precautionary action.
Global Influenza Vaccine Market: Segmentation
The global influenza vaccine market can be segmented into age group, technology, type, vaccine type, route of administration, and region.
By age group, the market can be segmented into pediatric and adults.
By technology, the market can be segmented into cell-based and egg-based. The cell-based segment holds the largest share in the global influenza vaccine market owing to the significant spike in surgical procedures all around the world.
By type, the market can be segmented into seasonal and pandemic. The seasonal influenza vaccine segment dominates the global influenza vaccine market owing to the high consumption of influenza vaccines more frequently in changing seasons. However, the pandemic influenza vaccine segment is expected to be the fastest-growing region in the global influenza vaccine market due to the outbreak of the Covid-19 pandemic globally.
By vaccine type, the market can be segmented into trivalent and quadrivalent. The quadrivalent segment accounts for the largest share in the global influenza vaccine market due to its easy availability, high efficacy against viral infections, and cost-effectiveness.
By route of administration, the market can be segmented into nasal spray and injection.
Global Influenza Vaccine Market: Regional analysis
North America accounts for the largest share in the global influenza vaccine market due to the high prevalence of infectious diseases in the region. In addition, the growing awareness among people regarding the influenza vaccine will further accentuate the demand in the regional market. Also, the devastating impact of the Covid-19 pandemic in the region is posing a huge demand for influenza vaccines. Furthermore, the region is likely to be the largest consumer of these vaccines in the forthcoming years. The constantly growing geriatric population in the region will also pose a large-scale demand for influenza vaccines.
Asia Pacific is expected to be the fastest-growing region in the global influenza vaccine market due to the presence of prominent market leaders in the region. Also, the outbreak of the Covid-19 pandemic in the region has led the governments to focus on influenza and flu vaccines to combat the surging symptoms amid this pandemic.
Global Influenza Vaccine Market: Competitive Players
Some of the significant players in the global influenza vaccine market are Sinovac Biotech Ltd., Sanofi, Pfizer, Inc., Novartis Ag, Merck & Co., Inc., GlaxoSmithKline Plc, Gamma Vaccines Pty Ltd., F. Hoffmann-La Roche Ltd., Emergent Biosolutions, Csl Limited, Biodiem, and AstraZeneca Plc.
Global Influenza Vaccine Market: Regional Segment Analysis
What Reports Provides
Request the coronavirus impact analysis across industries and markets
The growing prevalence of influenza epidemics is likely to steer the growth of the global influenza vaccine market during the forecast period. The frequent seasonal outbreaks globally are further likely to expand the sales of such vaccine products over the projected period. The constantly growing government support and favorable policies regarding vaccination against viruses like influenza on the global level are likely to further support the market.
Some of the significant players in the global influenza vaccine market are Sinovac Biotech Ltd., Sanofi, Pfizer, Inc., Novartis Ag, Merck & Co., Inc., GlaxoSmithKline Plc, Gamma Vaccines Pty Ltd., F. Hoffmann-La Roche Ltd., Emergent Biosolutions, Csl Limited, Biodiem, and AstraZeneca Plc.
North America accounts for the largest share in the global influenza vaccine market due to the high prevalence of infectious diseases in the region. In addition, the growing awareness among people regarding the influenza vaccine will further accentuate the demand in the regional market.
Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No 020-46277770
US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed